Prospective Trial Data on MRD Testing in Early-Stage CRC

Opinion
Video

An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.

Recent Videos
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content